Proteins > Indoleamine 2,3-dioxygenase 1
Page last updated: 2024-08-07 18:30:46
Indoleamine 2,3-dioxygenase 1
An indoleamine 2,3-dioxygenase 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P14902]
Synonyms
IDO-1;
EC 1.13.11.52;
Indoleamine-pyrrole 2,3-dioxygenase
Research
Bioassay Publications (65)
Timeframe | Studies on this Protein(%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (9.23) | 29.6817 |
2010's | 46 (70.77) | 24.3611 |
2020's | 13 (20.00) | 2.80 |
Compounds (88)
Drugs with Inhibition Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
tryptamine | Homo sapiens (human) | Ki | 158.0000 | 2 | 2 |
oxyquinoline | Homo sapiens (human) | IC50 | 750.0000 | 1 | 1 |
bay h 4502 | Homo sapiens (human) | IC50 | 23.0000 | 1 | 1 |
dichlorophen | Homo sapiens (human) | IC50 | 70.0000 | 1 | 1 |
benzophenone | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
ebselen | Homo sapiens (human) | Ki | 0.0940 | 3 | 3 |
econazole | Homo sapiens (human) | IC50 | 4.6000 | 2 | 2 |
phenelzine | Homo sapiens (human) | IC50 | 14.0000 | 1 | 1 |
isoconazole | Homo sapiens (human) | IC50 | 23.0000 | 1 | 1 |
juglone | Homo sapiens (human) | IC50 | 1.0000 | 2 | 2 |
ketoconazole | Homo sapiens (human) | IC50 | 28.5000 | 2 | 2 |
beta-lapachone | Homo sapiens (human) | IC50 | 0.7200 | 4 | 4 |
beta-lapachone | Homo sapiens (human) | Ki | 0.1000 | 2 | 2 |
vitamin k 3 | Homo sapiens (human) | IC50 | 0.8925 | 4 | 4 |
miconazole | Homo sapiens (human) | IC50 | 3.7000 | 4 | 4 |
sulconazole | Homo sapiens (human) | IC50 | 6.4000 | 1 | 1 |
mitomycin | Homo sapiens (human) | Ki | 25.0000 | 1 | 1 |
tryptophan | Homo sapiens (human) | IC50 | 498.7000 | 1 | 1 |
lawsone | Homo sapiens (human) | IC50 | 675.0000 | 1 | 1 |
3-hydroxy-2-naphthoic acid | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
benzotriazole | Homo sapiens (human) | IC50 | 2,570.0000 | 1 | 1 |
benzothiazole | Homo sapiens (human) | IC50 | 652.0000 | 1 | 1 |
phenylhydrazine | Homo sapiens (human) | IC50 | 0.5933 | 3 | 3 |
phenylhydroxylamine | Homo sapiens (human) | IC50 | 9.2000 | 1 | 1 |
4-aminodiphenylamine | Homo sapiens (human) | IC50 | 400.0000 | 1 | 1 |
4-chloroaniline | Homo sapiens (human) | IC50 | 1,553.0000 | 2 | 2 |
dichlone | Homo sapiens (human) | IC50 | 0.2800 | 2 | 2 |
dibenzothiazyl disulfide | Homo sapiens (human) | IC50 | 500.0000 | 1 | 1 |
1,4-naphthoquinone | Homo sapiens (human) | IC50 | 2.6860 | 5 | 5 |
9-fluorenone | Homo sapiens (human) | IC50 | 200.0000 | 1 | 1 |
benzohydroxamic acid | Homo sapiens (human) | IC50 | 16.0000 | 1 | 1 |
1,2-naphthoquinone | Homo sapiens (human) | IC50 | 7.1000 | 2 | 2 |
benzylhydrazine | Homo sapiens (human) | IC50 | 71.0000 | 1 | 1 |
1,4-naphthohydroquinone | Homo sapiens (human) | IC50 | 5.7500 | 2 | 2 |
2-hydrazinobenzothiazole | Homo sapiens (human) | IC50 | 35.1500 | 2 | 2 |
3-phenylpyridine | Homo sapiens (human) | IC50 | 161.0000 | 2 | 2 |
2-methoxy-1,4-naphthoquinone | Homo sapiens (human) | IC50 | 0.7200 | 2 | 2 |
6,7-Dimethyl-9-(2-acetoxyethyl)isoalloxazine | Homo sapiens (human) | IC50 | 515.6500 | 2 | 2 |
1-(2-(2,4-dichlorophenyl)-2-hydroxyethyl)-1h-imidazole | Homo sapiens (human) | IC50 | 130.0000 | 1 | 1 |
enilconazole | Homo sapiens (human) | IC50 | 23.0000 | 1 | 1 |
phenthiazamine | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
chaetochromin | Homo sapiens (human) | IC50 | 44.0900 | 1 | 1 |
norharman | Homo sapiens (human) | IC50 | 90.0000 | 1 | 1 |
norharman | Homo sapiens (human) | Ki | 90.0600 | 2 | 2 |
sertaconazole | Homo sapiens (human) | IC50 | 6.1000 | 2 | 2 |
4-chlorophenethylamine | Homo sapiens (human) | IC50 | 60.0000 | 2 | 2 |
harmol | Homo sapiens (human) | IC50 | 2,000.0000 | 1 | 1 |
4(5)-phenylimidazole | Homo sapiens (human) | IC50 | 76.7824 | 17 | 17 |
4(5)-phenylimidazole | Homo sapiens (human) | Ki | 4.4000 | 1 | 1 |
alpha-lapachone | Homo sapiens (human) | IC50 | 4.3400 | 2 | 2 |
xyloidone | Homo sapiens (human) | IC50 | 0.2140 | 2 | 2 |
chrysomycin a | Homo sapiens (human) | IC50 | 126.3000 | 2 | 2 |
tryptanthrine | Homo sapiens (human) | IC50 | 10,842.6107 | 5 | 3 |
tryptanthrine | Homo sapiens (human) | Ki | 4.8100 | 2 | 1 |
fluoren-9-ol | Homo sapiens (human) | IC50 | 1,000.0000 | 1 | 1 |
2-phenylisatogen | Homo sapiens (human) | IC50 | 2.0567 | 3 | 3 |
4-nitrobenzyloxyamine | Homo sapiens (human) | IC50 | 2.7000 | 1 | 1 |
4-(2-thiazolylazo)resorcinol | Homo sapiens (human) | IC50 | 45.0400 | 1 | 1 |
1-methyltryptophan | Homo sapiens (human) | IC50 | 247.4225 | 4 | 4 |
1-methyltryptophan | Homo sapiens (human) | Ki | 46.0000 | 6 | 7 |
2-phenylindolone | Homo sapiens (human) | IC50 | 114.0000 | 1 | 1 |
benzyloxyamine | Homo sapiens (human) | IC50 | 5.4050 | 2 | 2 |
4-hydroxycarbazole | Homo sapiens (human) | IC50 | 400.0000 | 1 | 1 |
cinnabarinic acid | Homo sapiens (human) | IC50 | 0.4600 | 1 | 1 |
cinnabarinic acid | Homo sapiens (human) | Ki | 0.3260 | 1 | 1 |
celastrol | Homo sapiens (human) | IC50 | 8.4100 | 1 | 1 |
cryptotanshinone | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
tanshinone ii a | Homo sapiens (human) | IC50 | 10.0000 | 1 | 1 |
nsc 36398 | Homo sapiens (human) | Ki | 100.0000 | 1 | 1 |
Porfiromycine | Homo sapiens (human) | IC50 | 507.8500 | 2 | 2 |
6,11-dioxo-12-naphtho[2,3-b]indolizinecarboxylic acid ethyl ester | Homo sapiens (human) | IC50 | 0.3320 | 1 | 1 |
nsc228155 | Homo sapiens (human) | IC50 | 66.0000 | 2 | 2 |
3-(1h-indol-3-yl)pyrrolidine-2,5-dione | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
indoximod | Homo sapiens (human) | IC50 | 15,198.9000 | 7 | 7 |
indoximod | Homo sapiens (human) | Ki | 30.5000 | 4 | 4 |
5-amino-8-hydroxyquinoline | Homo sapiens (human) | IC50 | 3.0000 | 1 | 1 |
benzyloxycarbonylleucyl-leucyl-leucine aldehyde | Homo sapiens (human) | IC50 | 0.5000 | 1 | 1 |
2-(3-Chloro-2-fluorophenyl)-2,3-dihydroisothiazol-3-one | Homo sapiens (human) | IC50 | 71.9333 | 3 | 3 |
tenatoprazole | Homo sapiens (human) | IC50 | 100.0000 | 1 | 1 |
1-methyltryptophan | Homo sapiens (human) | IC50 | 158.7535 | 22 | 20 |
1-methyltryptophan | Homo sapiens (human) | Ki | 30.1000 | 11 | 10 |
captax | Homo sapiens (human) | IC50 | 126.0000 | 1 | 1 |
4-(3-chlorophenyl)thiosemicarbazide | Homo sapiens (human) | IC50 | 15.0000 | 1 | 1 |
N-(2-chlorophenyl)hydrazine-1-carbothioamide | Homo sapiens (human) | IC50 | 50.0000 | 1 | 1 |
1-(4-hydroxyphenyl)-3-(3-methoxyphenyl)thiourea | Homo sapiens (human) | IC50 | 195.8500 | 2 | 2 |
methyl-thiohydantoin-tryptophan | Homo sapiens (human) | IC50 | 63.6267 | 6 | 6 |
methyl-thiohydantoin-tryptophan | Homo sapiens (human) | Ki | 11.5600 | 5 | 5 |
4-phenyl-3H-thiazole-2-thione | Homo sapiens (human) | IC50 | 25.6086 | 3 | 4 |
brassinin | Homo sapiens (human) | Ki | 76.3500 | 4 | 4 |
ethyl 4-(3-oxo-2,3-dihydroisothiazol-2-yl)benzoate | Homo sapiens (human) | IC50 | 42.0000 | 3 | 3 |
oxiconazole | Homo sapiens (human) | IC50 | 28.0000 | 1 | 1 |
680c91 | Homo sapiens (human) | IC50 | 413.8000 | 2 | 2 |
beta-3-oxindolylalanine | Homo sapiens (human) | IC50 | 3.3900 | 1 | 1 |
trans-avicennol | Homo sapiens (human) | Ki | 635.0000 | 1 | 1 |
stf 083010 | Homo sapiens (human) | IC50 | 1.3900 | 1 | 1 |
Drugs with Activation Measurements
Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
indazoles | Homo sapiens (human) | Kd | 220.5000 | 2 | 2 |
indoximod | Homo sapiens (human) | EC50 | 110.0000 | 1 | 1 |
1-methyltryptophan | Homo sapiens (human) | EC50 | 119.8300 | 2 | 2 |
Drugs with Other Measurements
Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.MedChemComm, , Oct-01, Volume: 10, Issue:10, 2019
Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.Journal of medicinal chemistry, , Dec-24, Volume: 58, Issue:24, 2015
Investigation of chalcogen bioisosteric replacement in a series of heterocyclic inhibitors of tryptophan 2,3-dioxygenase.European journal of medicinal chemistry, , Jan-05, Volume: 227, 2022
Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.MedChemComm, , Oct-01, Volume: 10, Issue:10, 2019
Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.Journal of medicinal chemistry, , Dec-24, Volume: 58, Issue:24, 2015
Investigation of multi-target-directed ligands (MTDLs) with butyrylcholinesterase (BuChE) and indoleamine 2,3-dioxygenase 1 (IDO1) inhibition: The design, synthesis of miconazole analogues targeting Alzheimer's disease.Bioorganic & medicinal chemistry, , 05-01, Volume: 26, Issue:8, 2018
Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.European journal of medicinal chemistry, , Sep-12, Volume: 84, 2014
Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective.Journal of medicinal chemistry, , 12-24, Volume: 63, Issue:24, 2020
Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.MedChemComm, , Oct-01, Volume: 10, Issue:10, 2019
Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1).Journal of medicinal chemistry, , 10-10, Volume: 62, Issue:19, 2019
Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.Journal of medicinal chemistry, , Dec-24, Volume: 58, Issue:24, 2015
Polyketides and Anthranilic Acid Possessing 6-Deoxy-α-l-talopyranose from a Streptomyces Species.Journal of natural products, , 05-26, Volume: 80, Issue:5, 2017
Identification of potent virtual leads to design novel indoleamine 2,3-dioxygenase inhibitors: pharmacophore modeling and molecular docking studies.European journal of medicinal chemistry, , Volume: 45, Issue:9, 2010
Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.Journal of medicinal chemistry, , Mar-27, Volume: 51, Issue:6, 2008
Novel BuChE-IDO1 inhibitors from sertaconazole: Virtual screening, chemical optimization and molecular modeling studies.Bioorganic & medicinal chemistry letters, , 02-15, Volume: 34, 2021
Investigation of multi-target-directed ligands (MTDLs) with butyrylcholinesterase (BuChE) and indoleamine 2,3-dioxygenase 1 (IDO1) inhibition: The design, synthesis of miconazole analogues targeting Alzheimer's disease.Bioorganic & medicinal chemistry, , 05-01, Volume: 26, Issue:8, 2018
Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.European journal of medicinal chemistry, , Sep-12, Volume: 84, 2014
Recent synthetic and medicinal perspectives of tryptanthrin.Bioorganic & medicinal chemistry, , 09-01, Volume: 25, Issue:17, 2017
N (1)-Fluoroalkyltryptophan Analogues: Synthesis and in vitro Study as Potential Substrates for Indoleamine 2,3-Dioxygenase.ACS medicinal chemistry letters, , Mar-12, Volume: 6, Issue:3, 2015
O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1.European journal of medicinal chemistry, , Jan-27, Volume: 108, 2016
Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1).Bioorganic & medicinal chemistry, , Dec-15, Volume: 21, Issue:24, 2013
Bifunctional Naphthoquinone Aromatic Amide-Oxime Derivatives Exert Combined Immunotherapeutic and Antitumor Effects through Simultaneous Targeting of Indoleamine-2,3-dioxygenase and Signal Transducer and Activator of Transcription 3.Journal of medicinal chemistry, , 02-27, Volume: 63, Issue:4, 2020
Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions.European journal of medicinal chemistry, , Jan-27, Volume: 126, 2017
Identification of potent virtual leads to design novel indoleamine 2,3-dioxygenase inhibitors: pharmacophore modeling and molecular docking studies.European journal of medicinal chemistry, , Volume: 45, Issue:9, 2010
Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors.Journal of medicinal chemistry, , Mar-27, Volume: 51, Issue:6, 2008
Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective.Journal of medicinal chemistry, , 12-24, Volume: 63, Issue:24, 2020
Novel indoleamine 2,3-dioxygenase-1 inhibitors from a multistep in silico screen.Bioorganic & medicinal chemistry, , Feb-01, Volume: 20, Issue:3, 2012
Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors.Bioorganic & medicinal chemistry, , Feb-15, Volume: 19, Issue:4, 2011
Novel BuChE-IDO1 inhibitors from sertaconazole: Virtual screening, chemical optimization and molecular modeling studies.Bioorganic & medicinal chemistry letters, , 02-15, Volume: 34, 2021
Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.European journal of medicinal chemistry, , Sep-12, Volume: 84, 2014
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy.European journal of medicinal chemistry, , Jan-05, Volume: 227, 2022
Azole-Based Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.Journal of medicinal chemistry, , 02-25, Volume: 64, Issue:4, 2021
Discovery of Clinical Candidate (1Journal of medicinal chemistry, , 07-25, Volume: 62, Issue:14, 2019
Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1).Journal of medicinal chemistry, , 10-10, Volume: 62, Issue:19, 2019
Identification of Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors Based on a Phenylimidazole Scaffold.ACS medicinal chemistry letters, , Feb-08, Volume: 9, Issue:2, 2018
Identification and preliminary structure-activity relationships of 1-Indanone derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors.Bioorganic & medicinal chemistry, , 07-15, Volume: 25, Issue:14, 2017
Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions.European journal of medicinal chemistry, , Jan-27, Volume: 126, 2017
New Inhibitors of Indoleamine 2,3-Dioxygenase 1: Molecular Modeling Studies, Synthesis, and Biological Evaluation.Journal of medicinal chemistry, , 11-10, Volume: 59, Issue:21, 2016
Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway.Journal of medicinal chemistry, , Nov-25, Volume: 58, Issue:22, 2015
Aminophenoxazinones as inhibitors of indoleamine 2,3-dioxygenase (IDO). Synthesis of exfoliazone and chandrananimycin A.Journal of medicinal chemistry, , Apr-25, Volume: 56, Issue:8, 2013
Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase.Journal of medicinal chemistry, , Aug-28, Volume: 51, Issue:16, 2008
Recent synthetic and medicinal perspectives of tryptanthrin.Bioorganic & medicinal chemistry, , 09-01, Volume: 25, Issue:17, 2017
Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice.Journal of medicinal chemistry, , Nov-14, Volume: 56, Issue:21, 2013
[no title available],
Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy.European journal of medicinal chemistry, , Jan-01, Volume: 143, 2018
Discovery of imidazoleisoindole derivatives as potent IDO1 inhibitors: Design, synthesis, biological evaluation and computational studies.European journal of medicinal chemistry, , Nov-10, Volume: 140, 2017
Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway.Journal of medicinal chemistry, , Nov-25, Volume: 58, Issue:22, 2015
Discovery and structure-activity relationships of phenyl benzenesulfonylhydrazides as novel indoleamine 2,3-dioxygenase inhibitors.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 24, Issue:15, 2014
Synthesis and biological evaluation of novel tryptoline derivatives as indoleamine 2,3-dioxygenase (IDO) inhibitors.Bioorganic & medicinal chemistry, , Mar-01, Volume: 21, Issue:5, 2013
Structure-activity relationship and enzyme kinetic studies on 4-aryl-1H-1,2,3-triazoles as indoleamine 2,3-dioxygenase (IDO) inhibitors.European journal of medicinal chemistry, , Volume: 46, Issue:11, 2011
Synthesis of indoleamine 2,3-dioxygenase inhibitory analogues of the sponge alkaloid exiguamine A.Journal of medicinal chemistry, , May-08, Volume: 51, Issue:9, 2008
O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1.European journal of medicinal chemistry, , Jan-27, Volume: 108, 2016
Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.Journal of medicinal chemistry, , Dec-24, Volume: 58, Issue:24, 2015
4,6-Disubstituted-1H-Indazole-4-Amine derivatives with immune-chemotherapy effect and in vivo antitumor activity.European journal of medicinal chemistry, , Nov-05, Volume: 241, 2022
Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.European journal of medicinal chemistry, , Aug-05, Volume: 238, 2022
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy.European journal of medicinal chemistry, , Jan-05, Volume: 227, 2022
X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson's Disease.Journal of medicinal chemistry, , 06-24, Volume: 64, Issue:12, 2021
Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective.Journal of medicinal chemistry, , 12-24, Volume: 63, Issue:24, 2020
Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy.European journal of medicinal chemistry, , Jan-01, Volume: 143, 2018
Discovery of indoleamine 2,3-dioxygenase inhibitors using machine learning based virtual screening.MedChemComm, , Jun-01, Volume: 9, Issue:6, 2018
Identification and preliminary structure-activity relationships of 1-Indanone derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors.Bioorganic & medicinal chemistry, , 07-15, Volume: 25, Issue:14, 2017
Development of Indoleamine 2,3-Dioxygenase 1 Inhibitors for Cancer Therapy and Beyond: A Recent Perspective.Journal of medicinal chemistry, , 12-24, Volume: 63, Issue:24, 2020
Design, synthesis and biological evaluation of novel aryl-acrylic derivatives as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
[no title available]Journal of medicinal chemistry, , 10-24, Volume: 62, Issue:20, 2019
Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.MedChemComm, , Oct-01, Volume: 10, Issue:10, 2019
Tryptophan 2,3-dioxygenase inhibitory activities of tryptanthrin derivatives.European journal of medicinal chemistry, , Dec-05, Volume: 160, 2018
Synthesis and evaluation of oxindoles as promising inhibitors of the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1.MedChemComm, , Aug-01, Volume: 8, Issue:8, 2017
Discovery of potent IDO1 inhibitors derived from tryptophan using scaffold-hopping and structure-based design approaches.European journal of medicinal chemistry, , Sep-29, Volume: 138, 2017
1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2).Bioorganic & medicinal chemistry letters, , 09-01, Volume: 26, Issue:17, 2016
Fused Heterocyclic Compounds as Potent Indoleamine-2,3-dioxygenase 1 Inhibitors.ACS medicinal chemistry letters, , Dec-08, Volume: 7, Issue:12, 2016
N (1)-Fluoroalkyltryptophan Analogues: Synthesis and in vitro Study as Potential Substrates for Indoleamine 2,3-Dioxygenase.ACS medicinal chemistry letters, , Mar-12, Volume: 6, Issue:3, 2015
Thiosemicarbazide, a fragment with promising indolamine-2,3-dioxygenase (IDO) inhibition properties.European journal of medicinal chemistry, , Jul-23, Volume: 82, 2014
Discovery of tryptanthrin derivatives as potent inhibitors of indoleamine 2,3-dioxygenase with therapeutic activity in Lewis lung cancer (LLC) tumor-bearing mice.Journal of medicinal chemistry, , Nov-14, Volume: 56, Issue:21, 2013
Indoleamine 2,3-dioxygenase inhibitory activity of derivatives of marine alkaloid tsitsikammamine A.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 23, Issue:1, 2013
Novel indoleamine 2,3-dioxygenase-1 inhibitors from a multistep in silico screen.Bioorganic & medicinal chemistry, , Feb-01, Volume: 20, Issue:3, 2012
Discovery and preliminary SARs of keto-indoles as novel indoleamine 2,3-dioxygenase (IDO) inhibitors.European journal of medicinal chemistry, , Volume: 46, Issue:7, 2011
Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors.Bioorganic & medicinal chemistry, , Feb-15, Volume: 19, Issue:4, 2011
Rational design of indoleamine 2,3-dioxygenase inhibitors.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Synthesis and biological activity of 1-methyl-tryptophan-tirapazamine hybrids as hypoxia-targeting indoleamine 2,3-dioxygenase inhibitors.Bioorganic & medicinal chemistry, , Sep-15, Volume: 16, Issue:18, 2008
Indoleamine 2,3-dioxygenase inhibitors from the Northeastern Pacific Marine Hydroid Garveia annulata.Journal of natural products, , Volume: 69, Issue:10, 2006
[no title available],
Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and PROTAC-based degraders for cancer therapy.European journal of medicinal chemistry, , Jan-05, Volume: 227, 2022
Small-Molecule Inhibitors of Necroptosis: Current Status and Perspectives.Journal of medicinal chemistry, , 02-27, Volume: 63, Issue:4, 2020
Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.MedChemComm, , Oct-01, Volume: 10, Issue:10, 2019
Discovery of potent IDO1 inhibitors derived from tryptophan using scaffold-hopping and structure-based design approaches.European journal of medicinal chemistry, , Sep-29, Volume: 138, 2017
Non-kinase targets of protein kinase inhibitors.Nature reviews. Drug discovery, , Volume: 16, Issue:6, 2017
Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.Journal of medicinal chemistry, , Dec-24, Volume: 58, Issue:24, 2015
Challenges and Opportunities in the Discovery of New Therapeutics Targeting the Kynurenine Pathway.Journal of medicinal chemistry, , Nov-25, Volume: 58, Issue:22, 2015
Synthesis and biological evaluation of novel tryptoline derivatives as indoleamine 2,3-dioxygenase (IDO) inhibitors.Bioorganic & medicinal chemistry, , Mar-01, Volume: 21, Issue:5, 2013
Synthesis of 4- and 5-arylthiazolinethiones as inhibitors of indoleamine 2,3-dioxygenase.Bioorganic & medicinal chemistry letters, , 08-01, Volume: 27, Issue:15, 2017
Rational design of indoleamine 2,3-dioxygenase inhibitors.Journal of medicinal chemistry, , Feb-11, Volume: 53, Issue:3, 2010
Synthesis and biological evaluation of novel tryptoline derivatives as indoleamine 2,3-dioxygenase (IDO) inhibitors.Bioorganic & medicinal chemistry, , Mar-01, Volume: 21, Issue:5, 2013
Indol-2-yl ethanones as novel indoleamine 2,3-dioxygenase (IDO) inhibitors.Bioorganic & medicinal chemistry, , Feb-15, Volume: 19, Issue:4, 2011
Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors.Journal of medicinal chemistry, , Jan-26, Volume: 49, Issue:2, 2006
Enables
This protein enables 5 target(s):
Target | Category | Definition |
electron transfer activity | molecular function | A molecular function representing the directed movement of electrons from one molecular entity to another, typically mediated by electron carriers or acceptors, resulting in the transfer of energy and/or the reduction-oxidation (redox) transformation of chemical species. This activity is fundamental to various biological processes, including cellular respiration and photosynthesis, as well as numerous enzymatic reactions involved in metabolic pathways. [Wikipedia:Electron_transfer] |
heme binding | molecular function | Binding to a heme, a compound composed of iron complexed in a porphyrin (tetrapyrrole) ring. [GOC:ai] |
indoleamine 2,3-dioxygenase activity | molecular function | Catalysis of the reaction: tryptophan + O2 = N-formylkynurenine. The product of the reaction depends on the substrate; D-tryptophan produces N-formyl-D-kynurenine, and L-tryptophan produces N-formyl-L-kynurenine. [EC:1.13.11.52] |
metal ion binding | molecular function | Binding to a metal ion. [GOC:ai] |
tryptophan 2,3-dioxygenase activity | molecular function | Catalysis of the reaction: L-tryptophan + O2 = N-formyl-L-kynurenine. [EC:1.13.11.11] |
Located In
This protein is located in 3 target(s):
Target | Category | Definition |
cytosol | cellular component | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. [GOC:hjd, GOC:jl] |
smooth muscle contractile fiber | cellular component | The contractile fiber of smooth muscle cells. [GOC:mah] |
stereocilium bundle | cellular component | A bundle of cross-linked stereocilia, arranged around a kinocilium on the apical surface of a sensory hair cell (e.g. a neuromast, auditory or vestibular hair cell). Stereocilium bundles act as mechanosensory organelles by responding to fluid motion or fluid pressure changes. [GOC:ecd, PMID:15661519, PMID:7840137] |
Active In
This protein is active in 1 target(s):
Target | Category | Definition |
cytoplasm | cellular component | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. [ISBN:0198547684] |
Involved In
This protein is involved in 18 target(s):
Target | Category | Definition |
positive regulation of T cell tolerance induction | biological process | Any process that activates or increases the frequency, rate, or extent of T cell tolerance induction. [GOC:add] |
positive regulation of chronic inflammatory response | biological process | Any process that activates or increases the frequency, rate, or extent of a chronic inflammatory response. [GOC:add] |
positive regulation of type 2 immune response | biological process | Any process that activates or increases the frequency, rate, or extent of a type 2 immune response. [GOC:add] |
tryptophan catabolic process | biological process | The chemical reactions and pathways resulting in the breakdown of tryptophan, the chiral amino acid 2-amino-3-(1H-indol-3-yl)propanoic acid. [ISBN:0198547684] |
inflammatory response | biological process | The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. [GO_REF:0000022, ISBN:0198506732] |
female pregnancy | biological process | The set of physiological processes that allow an embryo or foetus to develop within the body of a female animal. It covers the time from fertilization of a female ovum by a male spermatozoon until birth. [ISBN:0192800825] |
tryptophan catabolic process to kynurenine | biological process | The chemical reactions and pathways resulting in the breakdown of tryptophan into other compounds, including kynurenine. [GOC:go_curators] |
response to lipopolysaccharide | biological process | Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipopolysaccharide stimulus; lipopolysaccharide is a major component of the cell wall of gram-negative bacteria. [GOC:add, ISBN:0721601464] |
negative regulation of interleukin-10 production | biological process | Any process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-10 production. [GOC:mah] |
positive regulation of interleukin-12 production | biological process | Any process that activates or increases the frequency, rate, or extent of interleukin-12 production. [GOC:mah] |
multicellular organismal response to stress | biological process | Any process that results in a change in state or activity of a multicellular organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating the organism is under stress. The stress is usually, but not necessarily, exogenous (e.g. temperature, humidity, ionizing radiation). [GOC:mah] |
kynurenic acid biosynthetic process | biological process | The chemical reactions and pathways resulting in the formation of kynurenic acid, 4-hydroxyquinoline-2-carboxylic acid. [GOC:mah] |
swimming behavior | biological process | The response to external or internal stimuli that results in the locomotory process of swimming. Swimming is the self-propelled movement of an organism through the water. [GOC:cvs, PMID:16764679] |
T cell proliferation | biological process | The expansion of a T cell population by cell division. Follows T cell activation. [GOC:jl] |
negative regulation of T cell proliferation | biological process | Any process that stops, prevents or reduces the rate or extent of T cell proliferation. [GOC:jl] |
negative regulation of T cell apoptotic process | biological process | Any process that stops, prevents, or reduces the frequency, rate or extent of T cell death by apoptotic process. [GOC:add, GOC:mtg_apoptosis, ISBN:0781765196] |
positive regulation of T cell apoptotic process | biological process | Any process that activates or increases the frequency, rate or extent of T cell death by apoptotic process. [GOC:add, GOC:mtg_apoptosis, ISBN:0781765196] |
'de novo' NAD biosynthetic process from tryptophan | biological process | The chemical reactions and pathways resulting in the formation of nicotinamide adenine dinucleotide (NAD), beginning with the synthesis of tryptophan from simpler precursors; biosynthesis may be of either the oxidized form, NAD, or the reduced form, NADH. [PMID:17161604] |